MSD has received US Food and Drug Administration (FDA) approval for its anti-programmed death receptor-1 (PD-1) therapy, ...

Merck's Keytruda receives FDA approval for head and neck cancer after showing improved event-free survival in Phase 3 KEYNOTE ...

Pembrolizumab significantly reduced the risk of event free survival events by 30% compared with standard of care.

Merck & Co.’s Keytruda has become the first immunotherapy approved by the FDA to be used around surgery to treat resectable ...

Alvotech and Dr. Reddy’s have entered into a collaboration and license agreement to co-develop, manufacture and commercialize ...

Catherine was diagnosed with early TNBC, an aggressive form of breast cancer in November last year after her yearly mammogram. She was told Keytruda with chemotherapy would give her the best chance of ...

Keytruda marks the first perioperative anti-PD-1 treatment option for adults with PD-L1–positive resectable locally advanced ...

Keytruda was approved for locally advanced head and neck cancer before and after surgery, showing improved event-free ...

Released as a special project under the acclaimed Waiata Anthems musical series in time for the Matariki public holiday, ...

Merck has received approval from the Food and Drug Administration to expand use of its blockbuster drug, Keytruda, to treat ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the U.S. Food and Drug Administration ...

Merck & Co – known as MSD outside the US and Canada – has announced that its anti-PD-1 therapy Keytruda (pembrolizumab) has ...